

David A Scheinberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4388057/publications.pdf>

Version: 2024-02-01

81
papers

4,725
citations

159585

30
h-index

102487

66
g-index

85
all docs

85
docs citations

85
times ranked

8012
citing authors

#	ARTICLE	IF	CITATIONS
1	Engineering CAR-T cells to activate small-molecule drugs in situ. <i>Nature Chemical Biology</i> , 2022, 18, 216-225.	8.0	39
2	A TCR mimic monoclonal antibody reactive with the α -public β -phospho-neoantigen pIRS2/HLA-A*02:01 complex. <i>JCI Insight</i> , 2022, 7, .	5.0	8
3	A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A*02:01 complex. <i>PLoS ONE</i> , 2022, 17, e0265534.	2.5	4
4	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	12
5	A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies. <i>Blood</i> , 2022, 140, 861-874.	1.4	10
6	Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. <i>Nature Medicine</i> , 2022, 28, 946-957.	30.7	50
7	Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment. <i>Blood Advances</i> , 2022, 6, 4107-4121.	5.2	7
8	Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1189-1202.	4.2	7
9	Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy. <i>Oncotarget</i> , 2021, 10, 1916243.	4.6	15
10	Fibrillar pharmacology of functionalized nanocellulose. <i>Scientific Reports</i> , 2021, 11, 157.	3.3	8
11	Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. <i>Bioconjugate Chemistry</i> , 2021, 32, 649-654.	3.6	6
12	Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection. <i>Molecular Therapy</i> , 2021, 29, 3398-3409.	8.2	10
13	Alpha radioimmunotherapy using ^{225}Ac -proteus-DOTA for solid tumors - safety at curative doses. <i>Theranostics</i> , 2020, 10, 11359-11375.	10.0	26
14	CAR Chase: Where Do Engineered Cells Go in Humans?. <i>Frontiers in Oncology</i> , 2020, 10, 577773.	2.8	7
15	Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery. <i>Cancers</i> , 2020, 12, 2175.	3.7	17
16	An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments. <i>Journal of Proteomics</i> , 2020, 228, 103921.	2.4	2
17	Banning carbon nanotubes would be scientifically unjustified and damaging to innovation. <i>Nature Nanotechnology</i> , 2020, 15, 164-166.	31.5	69
18	A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with β -Particle-Emitting Ultrasmall Silica Nanoparticles. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 459-473.	1.0	13

#	ARTICLE	IF	CITATIONS
19	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 440-459.	9.4	103
20	Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform. <i>Cancer Immunology Research</i> , 2020, 8, 672-684.	3.4	25
21	Empirical and Rational Design of T Cell Receptor-Based Immunotherapies. <i>Frontiers in Immunology</i> , 2020, 11, 585385.	4.8	19
22	Solving an MHC allele-specific bias in the reported immunopeptidome. <i>JCI Insight</i> , 2020, 5, .	5.0	19
23	A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies. <i>Blood</i> , 2020, 136, 20-21.	1.4	1
24	Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. <i>Oncolmmunology</i> , 2019, 8, e1570778.	4.6	19
25	ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome. <i>Cancer Immunology Research</i> , 2019, 7, 1984-1997.	3.4	39
26	The effects of amine-modified single-walled carbon nanotubes on the mouse microbiota. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 5275-5286.	6.7	2
27	Epigenetic Drug Treatment Induces Presentation of New Class of Non-Exonic, Cryptic Neoantigens in Acute Myeloid Leukemia Cells. <i>Blood</i> , 2018, 132, 2717-2717.	1.4	2
28	Rejection of immunogenic tumor clones is limited by clonal fraction. <i>ELife</i> , 2018, 7, .	6.0	88
29	An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. <i>Oncolmmunology</i> , 2017, 6, e1252895.	4.6	20
30	Advances in the clinical translation of nanotechnology. <i>Current Opinion in Biotechnology</i> , 2017, 46, 66-73.	6.6	30
31	A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 7483-7489.	7.0	48
32	A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. <i>Journal of Clinical Investigation</i> , 2017, 127, 2705-2718.	8.2	63
33	Carbon nanotubes exhibit fibrillar pharmacology in primates. <i>PLoS ONE</i> , 2017, 12, e0183902.	2.5	18
34	Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. <i>Oncotarget</i> , 2017, 8, 14017-14028.	1.8	48
35	Opportunities and challenges for TCR mimic antibodies in cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 979-987.	3.1	45
36	Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1576-1582.	5.0	30

#	ARTICLE	IF	CITATIONS
37	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. <i>Cancer Immunology Research</i> , 2016, 4, 936-947.	3.4	132
38	Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity. <i>OncolImmunology</i> , 2016, 5, e1211221.	4.6	4
39	Acute myeloid leukaemia. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16010.	30.5	277
40	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , 2016, 17, 231.	8.8	746
41	Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. <i>Science Translational Medicine</i> , 2016, 8, 331ra39.	12.4	88
42	Deconvoluting hepatic processing of carbon nanotubes. <i>Nature Communications</i> , 2016, 7, 12343.	12.8	42
43	Remodeling the Vascular Microenvironment of Glioblastoma with ^{125}I -Particles. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1771-1777.	5.0	25
44	Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics. <i>Journal of Molecular Biology</i> , 2016, 428, 194-205.	4.2	48
45	Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (^{225}Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 4050-4050.	1.4	43
46	Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma. <i>Blood</i> , 2016, 128, 293-293.	1.4	0
47	Encapsulation of ^{125}I -Particle- ^{225}Ac Emitting ^{225}Ac Ions Within Carbon Nanotubes. <i>Journal of Nuclear Medicine</i> , 2015, 56, 897-900.	5.0	31
48	Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. <i>Nature Biotechnology</i> , 2015, 33, 1079-1086.	17.5	134
49	PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1700-1706.	6.4	13
50	A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias. <i>Blood</i> , 2015, 126, 2527-2527.	1.4	5
51	Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 (^{225}Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3794-3794.	1.4	8
52	Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein. <i>Clinical Cancer Research</i> , 2014, 20, 4036-4046.	7.0	46
53	Nontranscriptional Role of Hif-1 α in Activation of β -Secretase and Notch Signaling in Breast Cancer. <i>Cell Reports</i> , 2014, 8, 1077-1092.	6.4	122
54	Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with ^{225}Ac for ^{125}I -Particle Radioimmunotherapy of Cancer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1492-1498.	5.0	73

#	ARTICLE	IF	CITATIONS
55	A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. <i>Blood</i> , 2014, 123, 3296-3304.	1.4	52
56	Fibrillous Carbon Nanotube: An Unexpected Journey. <i>Critical Reviews in Oncogenesis</i> , 2014, 19, 261-268.	0.4	7
57	Carbon nanotubes as vaccine scaffolds. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 2016-2022.	13.7	62
58	Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody. <i>Science Translational Medicine</i> , 2013, 5, 176ra33.	12.4	147
59	Therapeutic Efficacy and Cure Of Sensitive and T315I Pan-Resistant Human Ph+ Leukemia In Mice Using a TCR-Like Antibody To WT1/HLA-A0201 Alone, Or In Combination With Tyrosine Kinase Inhibitors. <i>Blood</i> , 2013, 122, 855-855.	1.4	0
60	Familial Alzheimer Disease Presenilin-1 Mutations Alter the Active Site Conformation of β -secretase. <i>Journal of Biological Chemistry</i> , 2012, 287, 17288-17296.	3.4	58
61	Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR). <i>Blood</i> , 2012, 120, 3624-3624.	1.4	1
62	Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2482-2482.	1.4	1
63	Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. <i>Blood</i> , 2011, 118, 4817-4828.	1.4	1,135
64	Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 768-768.	1.4	27
65	Actinium-225 in Targeted Alpha-Particle Therapeutic Applications. <i>Current Radiopharmaceuticals</i> , 2011, 4, 306-320.	0.8	126
66	Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History. <i>Blood</i> , 2011, 118, 1765-1765.	1.4	0
67	A Cytotoxic Human Monoclonal Antibody Recognizing Cell Surface WT1 Peptide/HLA-A2 Complexes. <i>Blood</i> , 2011, 118, 1677-1677.	1.4	0
68	Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. <i>Seminars in Immunology</i> , 2010, 22, 162-172.	5.6	31
69	Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 266-276.	27.6	173
70	Multivalent DNA Aptamer-Based Therapeutic Agents for Lymphoma and Leukemia.. <i>Blood</i> , 2009, 114, 2711-2711.	1.4	0
71	Photo-Reactive and Non-Natural Amino Acid Epitopes of Human WT1 Enhance Immunogenicity and Allow Kinetic Study of Antigen Processing.. <i>Blood</i> , 2007, 110, 2311-2311.	1.4	1
72	CD4+ Peptide Epitopes from the WT1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Leukemia and Solid Tumor Cells.. <i>Blood</i> , 2006, 108, 3706-3706.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Remodeling Specific Immunity by Use of MHC-Tetramers Distinguishes Graft-Versus-Tumor Activity from Graft-Versus-Host-Disease.. Blood, 2005, 106, 1300-1300.	1.4	0
74	Generation of Specific Human CD8+ T Cell Responses to the Myeloproliferative Disorder Associated V617F Mutated JAK2 Kinase by Use of Analog Peptide Vaccine Candidates.. Blood, 2005, 106, 3512-3512.	1.4	0
75	Immune surveillance of leukemia?. Haematologica, 2005, 90, 1297B.	3.5	0
76	Sequential Therapy with Cytarabine and Bismuth-213 (213Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 1790-1790.	1.4	12
77	Generating Human Immune Responses to Mutations in Bcr-Abl Kinase Selected by Imatinib.. Blood, 2004, 104, 4689-4689.	1.4	0
78	Hematology: The Biological Therapy of Acute and Chronic Leukemia. Cancer Investigation, 1997, 15, 342-352.	1.3	4
79	A phase I study of anti-CD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer, 1995, 75, 2251-2257.	4.1	42
80	Murine and humanized constructs of monoclonal antibody m195 (anti-cd33) for the therapy of acute myelogenous leukemia. Cancer, 1994, 73, 1049-1056.	4.1	43
81	Neutral glycosphingolipid expression in B-cell neoplasms. International Journal of Cancer, 1991, 49, 837-845.	5.1	19